Scientists at the Ragon Institute â€“ a joint enterprise of Massachusetts General Hospital, the Massachusetts Institute of Technology and Harvard University formed in 2009 to bring together diverse disciplines to work on HIV â€“ “using a powerful mathematical tool previously applied to the stock market have identified an Achilles heel in HIV that could be a prime target for AIDS vaccines or drugs,” the Wall Street Journal reports.
John Dramani Mahama, vice president of the Republic of Ghana, recently spoke with NPR’s “Tell Me More” about how Ghana has made significant gains against HIV/AIDS, bringing the prevalence rate down to 1.5 percent from nearly 4 percent.
The WHO on Tuesday released its first-ever HIV guidelines on men who have sex with men (MSM) and transgender people, which “urge[s] governments to ensure gay men get equal access to HIV prevention and treatment services,” the Associated Press reports.
The recent achievements in studies looking at treatment as prevention “were only made possible by the partnership between publicly funded scientists and private drug companies,” Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.
Winstone Zulu, an adviser for AIDS-Free World and the coordinator of Health Triangle Zambia who walks with crutches because of a polio infection as a child, writes in a New York Times opinion piece that “people with disabilities are rarely exposed to sex education and are almost never considered in…
The success of antiretroviral therapy for HIV/AIDS “has fooled us into believing HIV is under control. It is not. â€¦ The fact remains that no sexually acquired infection has ever been controlled in democratic societies except by vaccines,” Lawrence Corey, president and director of the Fred Hutchinson Cancer Research Center and principal investigator of the international HIV Vaccine Trials Network, writes in a Wall Street Journal opinion piece.
Inter Press Service examines the changing scope of the U.N. Security Council. “[O]ver the years … the political landscape has been changing, slowly but steadily, as the U.N.’s most powerful body has continued to take up several ‘non-security’ related issues, including children and armed conflict (Aug. 1999), women, peace and security (Oct. 2000), climate change (Apr. 2007) and for the second time last week, HIV/AIDS,” IPS writes. The piece includes analysis from several experts affiliated with the U.N. (Deen, 6/17).
“U.S. first lady Michelle Obama left for Africa on Sunday, embarking on her second official solo journey abroad with a goal of advancing U.S. policies on education, health, and democracy,” Reuters reports.
In a post on State’s “DipNote” blog, U.S. Global AIDS Coordinator Ambassador Eric Goosby describes accompanying Secretary of State Hillary Rodham Clinton on her trip to Africa.
A new report from the consulting firm HCM Strategists and the nonprofit group FasterCures “analyzes the factors that helped patient advocates drive research into and drug development for [HIV/AIDS], and tries to figure out whether there are lessons to be learned for other disease advocates,” the Wall Street Journal’s “Health Blog” writes.